The fluorescent lights of a local pharmacy have a way of stripping the dignity from a person.
Arthur stands at the back of a long line, clutching a crumpled piece of paper that feels more like a ransom note than a prescription. He is seventy-two. He has worked forty years in a factory that smells of ozone and hot steel. He knows numbers. He knows that if you have ten bolts and you use six, you have four left. In Arthur’s world, math is a rigid, unyielding law. It is the thing that keeps the roof over his head.
But lately, the math coming out of Washington D.C. doesn’t work like factory math.
When Donald Trump stood before a crowd and insisted that drug prices were falling—citing "two ways of calculating" the data—he wasn't just talking about spreadsheets. He was talking about a fundamental shift in how reality is measured. The administration’s claim was bold: drug prices had seen their largest decrease in nearly half a century. To a policy wonk in a mahogany office, this is a victory lap. To Arthur, looking at the $240 charge for a vial of insulin that cost $40 a decade ago, it feels like a gaslighting campaign.
The disconnect lies in the shadow play of "list prices" versus "net prices."
The Ghost in the Machine
To understand why a president can claim prices are dropping while your bank account screams the opposite, you have to look at the machinery behind the curtain. Imagine a grocery store where every gallon of milk is labeled at $100. That is the list price. No one actually pays $100. The store gives a "rebate" to a middleman—let’s call him the Gatekeeper—who then decides how much of that discount to pass on to you.
If the Gatekeeper takes a $95 rebate and charges you $5, the "price" has technically stayed high, but your cost is low. If the store raises the label to $110 but gives a $106 rebate, the administration can claim the "net price" is falling.
This is the "two ways of calculating." One version looks at the sticker on the shelf. The other looks at the secret deal made in the back room.
The problem is that Arthur isn't part of the secret deal. He is one of the millions of Americans who pay based on the list price because their insurance reset its deductible, or because they fell into the "donut hole" of Medicare coverage. For these people, the "net price" is a ghost. You can’t pay for medicine with a ghost.
The administration’s insistence on these "impossible calculations" relies on a very specific set of data points from the Consumer Price Index. It’s a narrow lens. If you squint hard enough and ignore the soaring costs of new, life-saving specialty drugs, you can find a downward line on a graph. But graphs don't have to choose between buying groceries or buying blood thinners.
The Cost of the Curve
Numbers are often used as a shield. If a politician can convince you that the math is too complex for you to understand, they can convince you that your own lived experience is a fluke.
During the debates surrounding these figures, the White House pointed to a 1% drop in certain prescription indices. Economists quickly pointed out that this didn't account for the fact that the most used drugs—the ones that keep hearts beating and lungs clear—were still trekking upward at three times the rate of inflation.
Consider the hypothetical case of Sarah. Sarah is thirty-four, a freelance graphic designer with a penchant for marathon running and a Type 1 diabetes diagnosis. She is "underinsured." When the government talks about a 1% decrease in the price of generic antibiotics, it does nothing for her $600-a-month out-of-pocket insulin cost.
For Sarah, the political rhetoric feels like watching someone describe a rainstorm while she’s standing in a desert. The "two ways" of calculating aren't just different methods; they represent two different Americas. One America lives in the aggregate—the big, messy average where a billionaire and a beggar both "average out" to being wealthy. The other America lives in the specific, where the cost of a pill is the difference between a car payment and a medical miracle.
A Language of Deflection
There is a specific kind of theater involved in defending a mathematical impossibility. It requires a certain bravado, a refusal to blink when presented with a contradiction.
When the Bureau of Labor Statistics data failed to back up the claim of "historic" price drops, the narrative didn't change. It doubled down. This is a tactic as old as time: if the facts don't fit the story, change the way you measure the facts.
In the corporate world, this is called "creative accounting." In politics, it’s called a "platform."
By focusing on the "net price" (the price after secret rebates), the administration could ignore the "out-of-pocket" reality. It’s a clever sleight of hand. The manufacturer pays a rebate to the insurance company. The insurance company keeps a portion of that rebate as profit. The patient still pays a co-pay based on the original, bloated price.
Everyone wins, except the person with the prescription.
The Gatekeepers—known formally as Pharmacy Benefit Managers (PBMs)—are the silent architects of this confusion. They thrive in the gray area between the two ways of calculating. They are the reason the math doesn't add up for the consumer. As long as the calculation remains a matter of perspective rather than a matter of public record, the confusion serves those at the top.
The Weight of the Decimal Point
We often treat economics as a cold science, a series of pulleys and levers that move the world. We forget that every decimal point has a weight.
When a price "stabilizes" at an unaffordable level, it isn't a victory. It’s a stalemate. The administration’s insistence that the math was on their side was an attempt to claim a moral high ground using a flawed map.
If you tell a man in a pharmacy line that prices are falling, and he looks at his receipt and sees a rise, you aren't just arguing about economics. You are eroding the shared reality required for a functioning society. You are telling him that his eyes are lying, that his bank balance is an illusion, and that the "two ways" of seeing the world are more important than the one way he experiences it.
Arthur finally reaches the front of the line. The pharmacist, a woman who has seen this look a thousand times, speaks softly. She tells him the price. Arthur pauses. He does the mental math he’s done his whole life. He thinks about the bolts in the factory. Ten minus six is four.
He slides his credit card across the counter, knowing the balance will tip into the red.
The political world will continue to debate the formulas. They will argue over which index to use, which year to start the comparison, and which "way of calculating" sounds best on a 24-hour news cycle. They will treat the cost of medicine like a game of checkers, moving pieces across a board to achieve a strategic advantage.
But the board is made of people.
The numbers we choose to believe tell the story of who we value. When we choose a calculation that favors the Gatekeeper over the patient, we aren't just making a mistake in arithmetic. We are making a choice about whose life is worth the discount.
Arthur takes his bag. The plastic crinkles, a sharp, lonely sound in the quiet store. He walks out into the afternoon sun, a man who knows exactly what things cost, regardless of how many ways you try to count them.
